Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital

J Thromb Thrombolysis. 2021 May;51(4):1120-1126. doi: 10.1007/s11239-020-02258-6.

Abstract

Massive pulmonary embolism (PE), characterised by profound arterial hypotension, is a life-threatening emergency with a 90-day mortality of over 50%. Systemic thrombolysis can significantly reduce the risk of death or cardiovascular collapse in these patients, by around 50%, but these benefits are offset by a fivefold increased risk of intracranial haemorrhage and major bleeding, which may limit its use in patients at high risk of catastrophic haemorrhage. We describe a case series of 3 patients presenting with massive PE, each with extreme risk of bleeding and contra-indication to systemic thrombolysis, treated successfully with ultrasound-assisted, catheter directed thrombolysis (U-ACDT). Our experience of this novel technique using the EkoSonic Endovascular System (Ekos, BTG, London, UK) on carefully selected patients has demonstrated the potential to improve clinical status in shocked patients, with minimal bleed risk. There have been several clinical studies evaluating the Ekos system. Both the ULTIMA and SEATTLE II studies have shown significant reductions in RV/LV ratio by CT scanning when compared to standard anticoagulation in patients with intermediate-risk PE, with minimal bleeding complications. However, there is a pressing need for a randomised trial demonstrating improvement in robust clinical outcomes when comparing U-ACDT to simple anticoagulation. We believe that this case series adds new insight and highlights the potential of catheter directed thrombolysis in this high-risk patient cohort and consideration should be made to its use in cases where systemic thrombolysis is felt to be too high risk.

Keywords: Bleed risk; Catheter directed thrombolysis; Interventional cardiology; Massive Pulmonary Embolism; Thrombolysis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anticoagulants / therapeutic use
  • Catheters
  • Fibrinolytic Agents / therapeutic use
  • Hemorrhage
  • Hospitals, General*
  • Humans
  • Pulmonary Embolism* / drug therapy
  • Thrombolytic Therapy
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents